Levothyroxine and Liothyronine — Class I drug recall D-1181-2018

Terminated recall by Westminster Pharmaceuticals LLC, reported 2018-08-29, distributed nationwide. Failed Content Uniformity Specifications: Product was manufactured using an adulterated active pharmaceutical

Recall number	`D-1181-2018`
Product type	Drug
Classification	Class I
Status	Terminated
Voluntary or mandated	Voluntary
Recalling firm	Westminster Pharmaceuticals LLC, Olive Branch, MS, United States
Recall initiated	2018-08-03
Classified	2018-09-07
Reported by FDA	2018-08-29
Terminated	2020-06-03
Distributed	Nationwide (US)
Reason classes	labeling, potency, cgmp
NDC	`69367-0159-04`
Lot numbers	`15917VP01`, `15917VP02`, `15917VP03`, `15918001`, `15918002`, `15918003`, `15918004`, `15918005`, `15918006`, `15918007`, `15918VP01`, `15918VP02`, `15918VP03`
Expiration dates	`2019-10-31`, `2019-12-31`, `2020-02-29`, `2020-03-31`

Product

Levothyroxine and Liothyronine (Thyroid Tablets, USP), 1/4 grain (15 mg), 100-count bottles, Rx Only, Manufactured for: Westminster Pharmaceuticals, LLC, 154 Downing Street, Unit 1 & 2, Olive Branch, MS 38654, NDC 69367-159-04.

Reason for recall

Failed Content Uniformity Specifications: Product was manufactured using an adulterated active pharmaceutical ingredient; additionally, lack of process controls and good manufacturing practices resulted in finished product failing content uniformity specifications which can result in a product having a strength that is more or less than is labeled.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1181-2018. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.